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Down syndrome (DS) is the most common genetic cause
of intellectual disability, and it occurs in approximately 1 to
800 births. The prevalence of DS has increased lately
because of increased incidence and longer life expectancy
giving rise to an elderly population with DS that is at risk
for age-related comorbidities such as Alzheimer’s diseasethor. Tel.: 1212-998-9868; Fax: 1212-995-4603.
k5@nyu.edu
16/j.dadm.2016.01.001
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).(AD). More than 50% of DS subjects acquire dementia after
the age of 60. However, the age of dementia onset is highly
variable with both genetic and environmental factors
contributing to this variability. Thus, modifiable environ-
mental risk factors present a potentially relevant intervention
for DS persons at risk for AD. Among them, inflammation is
a potential target.
The purpose of this review is to explore the relationship
between inflammation, DS, and dementia using knowledge
gained from the study of sporadic and familial AD. It has
been increasingly recognized that peripheral chronic inflam-
mation and infections through their inflammatory andimer’s Association. This is an open access article under the CC BY-NC-ND
A.R. Kamer et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 49-5750bacterial burden are involved in the pathogenesis of AD [1].
Evidence also exists linking brain inflammation to the AD
pathology of DS subjects. However, it remains unknown
whether inflammation is downstream of core AD pathology
or is even an upstream phenomenon. DS patients are known
to have multiple comorbidities throughout their life. They
also have an aggressive form of periodontitis characterized
by rapid progression, significant bacterial/inflammatory
burden, and an onset as early as 6 years of age. This review
offers a rationale for examining periodontitis in DS as
a possible mechanism contributing to the high risk for AD
pathology.2. Alzheimer’s disease
AD is one of the leading causes of dementia afflicting the
elderly. The prevalence and incidence of AD increase with
age. Eleven percent of people older than 65 and 33% of those
.85 have AD.
2.1. Pathological features of AD
AD is a continuous process whose pathology starts years
before the onset of dementia. The pathological hallmarks of
AD are the presence of senile plaques, neurofibrillary tangles,
neuronal and synaptic dysfunction, and neuronal loss. The se-
nile plaques contain extracellular aggregates of amyloid-b
(Ab) peptide and activated glial cells, and reactive astrocytes
and inflammatory molecules associate intimately with these
plaques. Neurofibrillary tangles comprised phosphorylated
tau proteins, and the neuronal loss leads to brain atrophy.3. Alzheimer’s disease in DS
People with DS are at significant risk of developing AD.
In fact, according to the new International Working Group
Criteria, DS is conceptualized as a form of preclinical AD
[2]. Up to 28% of 30-year-old DS subjects develop cognitive
impairments but no dementia [3]. After 30, 40, and 60 years
of age, increasingly more DS people are diagnosed with de-
mentia reaching prevalence rates of 30%, 55%, and 77%,
respectively [3,4].
3.1. Pathological features in DS
The pathological hallmarks of AD, amyloid plaques, and
tangles accumulate in the brain of subjects with DS several
decades earlier than in the general population with sporadic
AD. The earliest amyloid depositions are thought to be
diffuse, nonfibrillar, and amorphous plaques, followed by
the development of the fibrillar plaques. A review of AD his-
topathological studies [5] in 398 DS subjects revealed that
subjects younger than 10 years old lacked AD plaques
and tangles. Then, in teens and in the 20–30 age range,
AD pathology affected approximately 7.5% and 16% of
brains, respectively. By age 40s, virtually all subjects had
AD pathology. The regional distribution of the plaques andtangles in DS subjects resembled that of late-onset sporadic
AD [5] although patterns resembling distribution of early-
onset AD have also been described.4. Pathogenesis of Alzheimer’s disease
4.1. Role of inflammation
Inflammation is thought to play a significant role [6]. Its
role can be primary [7], secondary, or a combination of
both. For example, Kristic and Knuesel [7] showed that
acute and chronic inflammation were able to induce AD-
related pathology and cognitive decline in animal models.
In this respect, in a thiamine-deficient model in which
chronic inflammation and oxidative stress were early
events, there was increased synthesis of Ab and amyloid
plaques [8], and antioxidants reversed the increased pro-
duction of Ab. Multiple reviews and animal studies support
the concept that pro-inflammatory cytokines and lipopoly-
saccharide (LPS) are stimulators of Ab production and tau
phosphorylation, and Ab and tau protein can induce in-
creases in cytokine. However, other studies showed that
inflammation could be induced secondarily by the core
AD pathological processes related to Ab cascade or tau-
related neurodegeneration.
4.2. Clinical studies
Three lines of clinical evidence support the role of
inflammation in AD: increased systemic inflammation, ge-
netic data, and the presence of infectious/inflammatory pe-
ripheral conditions. Pro-inflammatory molecules including
C-reactive protein (CRP), interleukin-6 (IL-6), and tumor-
necrosis factor-b (TNF-b) were associated with and
predicted poor cognition, cognitive decline, and dementia
2–25 years later. However, other studies failed to show
these cytokines as predictors of cognitive decline. This
discrepancy may be explained by the heterogeneous in-
flammatory responses dependent on timing and individual
differences in inflammatory genotypes. For example, we
have shown lower cognition in subjects with periodontal
inflammation than without [9]. However, among those
with periodontal inflammation, cognitive losses were
greater in those having IL-1082 AA/AG genotype [10].
Because subjects with IL-10-1082 AA/AG genotype pro-
duce less IL-10, an anti-inflammatory cytokine, IL-10-
1082 AA/AG genotype qualifies for a pro-inflammatory
phenotype. We also found that combination of the plasma
TNF-a with antibodies to specific periodontal bacteria (in-
dex of bacteria exposure and host response) increased the
discriminatory accuracy between normal (NL) and AD sub-
jects [11]. These findings consistent with Holmes [12] show
that a) peripheral infectious/inflammations are important in
the pathogenesis of AD, and b) perhaps, it is the combina-
tion between both peripheral infections/inflammations and
the magnitude of the host response, that is critical in under-
standing the pathophysiology of AD.
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several genes encoding proteins of the inflammatory-
immune system (PICALM, CLU, CR1, CR2, TREM2, and
CD33) are associated with AD [13]. Third, peripheral infec-
tions and inflammation are associated with and predict
cognitive decline and AD. Infectious agents such as cyto-
megalovirus [14] and herpes virus are associated with AD
pathology and cognitive dysfunction/AD and increase the
risk for AD. Peripheral inflammations with significant in-
flammatory burden such as diabetes, obesity, metabolic syn-
drome, and atherosclerosis are also associated with cognitive
dysfunction and are now accepted risks for AD [15].
4.3. Inflammatory mechanisms
The mechanisms by which the infections and inflamma-
tions affect the progression of the AD pathology are not
completely understood. Peripherally derived pro-
inflammatory molecules and bacteria/bacterial products
could reach the brain via systemic circulation and neural
pathways [16–18] or use macrophages/monocytes system
[19]. There, they increase the brain cytokine pool, promote
amyloid brain deposition, induce phosphorylation of tau
protein, decrease synaptic strength and neuronal degenera-
tion, and thus contribute to cognitive decline [18].5. Pathogenesis of AD in DS
5.1. Amyloid hypothesis
The pathogenesis of AD in DS has been recently re-
viewed [20,21]. Among the hypotheses put forward to
explain the AD in DS populations, amyloid-cascade hypoth-
esis is central [20]. DS is a trisomy characterized by the trip-
lication of chromosome 21 and amyloid precursor protein
(APP) gene, the precursor of amyloid b is located on this
chromosome. Thus, it is assumed that the overexpression
of APP accounts for the increased AD in DS subjects. The
amyloid-cascade hypothesis has its strongest evidence
derived from genetic studies in presenilin 1, presenilin 2,
or APPmutation carriers in which Ab overproduction is suf-
ficient to cause early-onset AD [4,22].
The rare families with an extra copy of the APP gene, in
which early-onset dementia develops, also support the cen-
tral role of the APP increased copy number. In these fam-
ilies, the duplication of an area of five to eight genes
including APP is sufficient to cause the disease [23]. As pre-
dicted by the APP increased copy number, these subjects
have abundant brain amyloid and tangle depositions and
wide spread cerebral amyloid angiopathy and intracerebral
hemorrhages [23]. However, compared with dementia in
people with DS, they are cognitively unimpaired before
the dementia and present much narrower age range for de-
mentia onset [24]. In contrast, although almost all DS sub-
jects have brain amyloid accumulation by age 40, the
dementia onset in DS is highly variable. The large interval
between amyloid accumulation and dementia onset suggeststhat many genetic and environmental factors may enhance or
mitigate the DS phenotype as pointed out in the literature
[22,25]. For example, mothers who gave birth to DS
children before age 35 were at increased risk of dementia
compared with those that gave birth after age 35, thus
implicating other genetic factors in AD [4].5.2. Inflammatory hypothesis
Another mechanism implicated in the increased risk of
AD in subjects with DS is the “oxidative inflammatory” hy-
pothesis. Wilcock and Griffin [26] proposed that several
genes of the chromosome 21 favor aM1 activation of the mi-
croglia similar to M1 activation of the macrophages. Macro-
phages are a population of cells with diverse functions in the
innate immune system. In humans, two main classes of acti-
vated macrophages have been described namelyM1 andM2.
Whereas LPS, granulocyte macrophage colony stimulating
factor and the TH1 cytokine interferon-gamma (IFN-g)
can trigger M1 macrophage activation, M2 activation can
be triggered by the TH2 cytokine IL-4, IL-13, and macro-
phage colony-stimulating factor. Furthermore, M1 activa-
tion leads to an inflammatory phenotype, whereas M2
activation favors an anti-inflammatory one. As described
previously, the IFN-g is one of the main M1 macrophage ac-
tivators in association with LPS and TNF-a. On binding to
its receptor that comprised the interferon-gamma receptor
1 (IFNGR-1) and IFNGR-2 chains, IFN activates a signal
transduction pathway involving activation of transcription
1 (STAT1) and interferon regulatory factors and induces in-
creases in cytokines such as IL-12, IL-23, IL-6, IL-1b, and
TNF-a and inhibition of IL-10. The genes encoding
IFNGR-2 and IFNAR-1 and IFNAR-2 genes are located
on chromosome 21. Therefore, their overexpression may
lead to a M1microglial activation with subsequent increased
production of pro-inflammatory cytokines [26]. Consistent
with this hypothesis, the pioneering work of Griffin found
that astrocytes and glial cells fromDS subjects had increased
expression of IL-1b, and S100 results in concurrence with
the recent findings of an inflammatory phenotype in the
brains of young DS subjects [27].
The genes of chromosome 21 encoding TIAM1, SOD1,
and PRMT can also contribute to AD in DS subjects by
increasing oxidative stress. Moreover, inflammation could
further stimulate SOD1 and provoke a self-perpetuating vi-
cious cycle with consequences on the brain.5.3. Priming of the glia
Peripheral infections/inflammations may interact with
the host immune response to induce a magnifying effect
on brain biology. The priming of the glial cells may explain
at least part of these effects [28]. Under homeostatic condi-
tions, microglia have a supportive role and sample the
neuro environment. When the neuro environment is chal-
lenged, the glial cells become activated. This activation is
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Then, the magnitude and length of response are increased
and damage can incur. Glial priming can occur naturally
by aging or by inflammatory/infectious conditions
throughout life [7,28], and still another priming can occur
by a genetic predisposition. DS is characterized by
upregulation of several genes predisposing to an
inflammatory phenotype [26]; therefore, glia in DS subjects
may respond with amplified effect when challenged by in-
fections/inflammations conditions.6. Periodontal disease
Periodontal disease (PerioD) is a polymicrobial, periph-
eral, chronic inflammatory disease that causes destruction
of the tissues surrounding the teeth. Clinically, chronic
periodontitis is characterized by the presence of gingival
erythema and edema and periodontal pockets and destruc-
tion of tissue supporting the teeth. Tissue destruction is
consistent with the existing local and systemic factors pre-
sent. Approximately, 45% of the dentate US adults between
30 and 90 years of age have some forms of PerioD although
only 8%–10% present with severe forms [29]. Two to
three percent of children have chronic periodontitis and
another 0.2%–2% have a severe form called aggressive
periodontitis [30].6.1. Pathogenesis of PerioD
There is an agreement that periodontal bacteria are
required for the initiation, maintenance, and progression of
PerioDs. Among them, Aggregatibacter actinomycetemco-
mitans, members of the red and orange clusters, such as Tan-
nerella forsythia, Porphyromonas gingivalis, Treponema
denticola, and Fusobacterium nucleatum, Prevotella inter-
media, Prevotella nigrescens, Parvimonas micra, Strepto-
coccus constellatus, Eubacterium nodatum, Campylobacter
showae, Campylobacter gracilis, and Campylobacter rectus
are considered important periodontal pathogens.
In addition to the above mentioned bacteria [31], other
components of microbiota have been found to contribute to
PerioD pathogenesis such as Porphyromonas endodontalis,
Treponema lecithinolyticum, Treponema medium, Filifactor
alocis, and Selenomonas sputigina. In addition, some bacte-
ria such as Veillonella parvula, Actinomyces sp., or the com-
bination of Streptococcus oralis, Streptococcus mitis, and
Streptococcus intermedius are considered beneficial and
may protect one from the PerioD (review [31]).
The oral microbiota constitute one of the most diverse
and abundant ecosystems in our body. Approximately,
1000 bacterial species colonize the oral cavity with any
particular individual holding .200 species. Up to 700 spe-
cies colonize the subgingival biofilm (under the gingival
line), and most are anaerobic. The diversity and abundance
of the specific bacteria in the biofilm are a function of a dy-
namic, multidirectional communication between bacteria,environment, host genetics, and its immune system. In peri-
odontal health, these factors lead to equilibrium consistent
with a symbiotic microbial ecosystem. In PerioD, these in-
terrelationships are compromised leading to structural and
functional disturbances within the bacterial community
called dysbiosis.
The mechanism by which periodontal dysbiosis occurs
is far from understood. The elegant studies of Hajishen-
gallis [32] showed that under predisposing conditions,
low abundance bacteria with immune subversive capabil-
ities, called keystone pathogens, are able to induce envi-
ronmental changes that are protective and growth
inducing to other bacterial species. In this altered environ-
ment, the commensal bacteria flourish, become patho-
bionts, and synergistically cause exaggerated local
inflammation and periodontal tissue breakdown. There is
considerable evidence that P. gingivalis is a keystone
pathogen. Aggregatibacter actinomycetemcomitans and
T. denticola have structural and physiological features
that could place them in the same category. This patho-
genic concept explains the presence of “disease-inducing
keystone” bacteria at periodontal healthy sites, shows
that the composition of the whole microbial population
is health or disease relevant, and the immune system plays
[32] a major role. Treatment of PerioD not only reduces
bacterial counts [33] but also causes shifts in bacterial
composition toward healthy microbiota.6.2. Mechanistic pathways for AD effects
Periodontal bacteria can get into the blood stream
frequently during daily procedures such as flossing, brush-
ing, and mastication particularly when periodontitis is pre-
sent. In the blood and then tissues, keystone pathogens and
other bacteria can further evade and subvert the immune sys-
tem and metastasize at distant sites inducing local inflamma-
tion [19]. Aggregatibacter actinomycetemcomitans, P.
gingivalis, and T. denticola were recovered in atheroscle-
rotic plaque. Brain abscesses in which oral bacteria were
implicated were reported.
It has been proposed that PerioD can initiate or contribute
to the AD pathogenesis through multiple pathways [18].
Infection-induced effects on AD have been reviewed criti-
cally in the literature [34–36]. A classic bacteria is
Treponema pallidum whose infection causes the atrophic
form of general paresis presenting with progressive
dementia and brain amyloid deposits. Miklossy [34] pro-
posed that oral bacteria including spirochetes could be
possible candidates to invade the brain and contribute to
AD pathology. Indeed, Riviere et al. [37] detected six
different periodontal pathogen treponemes in the brains in
.90% of the 16 AD cases analyzed. Moreover, P. gingiva-
lis–derived LPS was also detected in the brains of AD pa-
tients [38]. Subjects with PerioD have also a systemic
inflammation characterized by elevated levels of IL-1b,
IL-6, and TNF-a and CRP (meta-analysis) inflammation
A.R. Kamer et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 49-57 53that is thought to contribute to other inflammatory diseases
such as cardiovascular diseases, and cardiovascular diseases
are risk for AD.
Other mechanisms that have been proposed for PerioD-
induced systemic pathology include reduced masticatory
abilities, consequent dietary deficiencies, and increased
stress response. As shown for intestinal bacteria, other
mechanisms include modulation of nutrition and immune
system, enhancing production of neurotransmitters and bac-
terial metabolic products and neuronal communications.Fig. 1. Aggressive periodontitis in subjects with Down syndrome. The
panoramic radiography is from a 37-year-old man. Note: a) the bone loss
marked between the two lines is severe and extensive; and 2) multiple teeth
are lost due to periodontal disease.6.3. Clinical studies
Clinical data from our studies [9,39] and others using
various exposure indexes, study designs, and outcomes have
provided evidence of a link between PerioD and AD related
cognitive impairment [9,39,40]. For example, cross-
sectional studies have reported that measures of periodontal
dysbiosis were associated with cognitive impairment, cogni-
tive decline, dementia, and AD with odd ratios of mild-to-
moderate strength [41,42], and these studies have been
reviewed elsewhere [40]. Other studies did not find such an
association. Similarly, two longitudinal studies showed that
pocket depth and periodontal inflammation (current PerioD)
predicted cognitive decline with mild-to-moderate strength
(hazard ratio [HR] 5 1.05, 95% confidence interval [CI] 5
1.01–1.10 and odds ratio [OR] 5 1.57, 95% CI 5 1.01–
2.45) [43,44] although other studies did not support this
link. However, when PerioD was defined by immunological
parameters [45], the prediction was much stronger (OR 5
HR 5 3.1, 95% CI 5 1.5–6.4) [46]. Noticeable, Sparks
et al. [45] showed that subjects with AD had high immuno-
globulin G (IgG) antibodies to periodontal bacteria 10 years
before conversion when the subjects were NL indicating the
importance of periodontal bacteria in AD pathogenesis.
Most longitudinal studies (prospective, nested case–controls)
used tooth loss as a proxy of PerioD, and the results showed
significant associations in at least some populations with
OR between 1.05 and 2.38. Tooth loss is the ultimate outcome
of PerioD, but its association with the outcome measures can
be confounded by other factors. Tooth loss is used in most
cohort studies because of its convenient assessment, and it
can be obtained by subject report and can easily added to
an existing study. However, directmeasures of periodontal ex-
posures should be used. Stewart et al. [47] recognized that
there is little overlap between medical and dental research;
therefore, oral examinations are present in very few
medical-driven cohorts. Considering the high prevalence of
PerioD in the general population (46% in adults 30 and older),
even if PerioD has only a low-to-moderate effect, preventing
or treating it could prevent a significant number of AD cases
and, therefore, deserves unequivocal consideration. To date,
there are no longitudinal studies designed specifically to
assess the role of PerioD/oral health in AD incidence or
cognitive decline. Likewise, there are no studies assessing
the links between PerioD and AD in DS population.7. PerioD in DS
It is well established that people with DS have
increased severity and prevalence of PerioD relative to
NL population or other intellectually disabled populations.
Prevalence rates vary from study to study, but agreement
exists that they increase with age. A thorough review of
the literature [48,49] showed that 36% of children as
young as 6 years of age had pocket formation, a sign of
periodontal inflammation. Up to 40% of children as
young as 12 years of age had significant gingival
inflammation, pocket formation, and bone loss compared
with only 16% of non-DS subjects. After the age of 16,
58%–92% of DS and only approximately 20%–40% of
controls with other disabilities had PerioD [50], and these
results were consistent across different populations (USA,
New Zealand, and Finland). Oral hygiene (OH) is a signif-
icant confounder in any investigation, and DS population
has poorer OH compared with NL population. OH may
even differ within DS people because of intellectual and
physical disabilities. However, studies showed that OH
by itself could not account for differences in the PerioD
among DS, NL controls, or intellectually disabled controls
[51,52].
PerioD in DS subjects has the characteristics of an
aggressive periodontitis (Fig. 1). Compared with chronic
periodontitis, aggressive periodontitis affects younger popu-
lation, is severe, often has rapid progression, and the amount
of destruction is unexpected for a person of that age and
disproportional to the presence of local factors [53]. In DS,
PerioD has a significant inflammatory component [53] as
shown by the elevated inflammatory markers PGE2, TNF-
a, IFN-g, and SOD1 in their gingival crevicular fluid (local
inflammation) [54]. In addition, impaired immune responses
are characteristic of DS phenotype such as low IgA,
impaired neutrophil function, and increased inflammatory
responses to bacterial accumulation [55]. Although no study
investigated the DS-related periodontitis in relation to the
systemic CRP, subjects with aggressive periodontitis have
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The factors involved in the pathogenesis of PerioD in DS
subjects are not completely elucidated, but as in other forms
of periodontitis, bacteria play a significant role. Early colo-
nization by periodontal pathogens such as F. nucleatum, Pre-
votella species, A. Actinomycetemcomitans, P. gingivalis,
and spirochetes has been observed [50]. Moreover, DS chil-
dren aged13 harbored more frequently T. forsythia, T. den-
ticola, P. nigrescens, and C. rectus compared with non-DS
children with similar periodontal condition [49]. In adults,
the differences in microbiota between DS and non-DS
were not consistently found [56] although the red cluster
bacteria and A. actinomycetemcomitans were present in
high proportions in DS subjects with PerioD. In a larger
study, initial colonizers such as S. noxia, P. acnes, S. gordo-
nii, S. mitis, and S. oralis were found in higher proportion in
DS subjects compared with the non-DS ones, whereas T. soc-
ranskii was higher compared with intellectually challenged
subjects [57]. When interpreting these results, it is important
to bear in mind that most of these studies investigated only a
limited number of bacteria. Although Khocht study used
more advanced molecular techniques, they only assessed
40 bacterial species. Therefore, the analysis of the subgingi-
val microbiota with advanced molecular techniques is
needed to understand the intricacies of the relationshipsFig. 2. Model for periodontal disease (PerioD) contribution to Alzheimer’s disease
AD pathogenesis of DS is the presence of brain inflammation as illustrated by incre
(brain inflammatory pool). The PerioD-derived pro-inflammatory molecules and ba
pathways, contributing to 2. brain inflammation and inflammatory vicious cycle. T
subsequent cognitive decline. A pro-inflammatory genotype characteristic to DSbetween subgingival microbiota in DS and the host and the
potential for systemic effects.8. Model of periodontal effect on AD of DS
Periodontitis in DS subjects is severe and aggressive.
Therefore, it can contribute to brain inflammation, neurode-
generation, and cognitive decline. Fig. 2 offers a model by
which PerioD can contribute to AD pathogenesis in DS. In
general, PerioD in DS occurs before the onset of AD-
specific pathology and, therefore, can even be casual.
Periodontal bacteria colonize the oral and then peri-
odontal environment early in life. In subjects with DS, this
colonization by bacteria [49] such as P. gingivalis, T.
forsythia, and T. denticola is found as early as 2 years of
age compared with 4 years of age in non-DS subjects [49].
Several bacteria associated with DS-aggressive periodontitis
are capable of invading tissues including A. actinomycetem-
comitans, P. gingivalis, and T. denticola. P. gingivalis and
possible T. denticola are keystone pathogens with an
increased ability to evade the host response.
DS immune system is impaired, and defects in T-cell
maturation, B-cell function, and pro-oxidative state with
high levels of radical oxygen species have been described.
This weakened immune system could enhance colonization
by periodontal pathogens, weaken responses to these(AD) progression in peoplewith Down syndrome (DS). The central theme of
ases in pro-inflammatory cytokines, C-reactive protein, and oxidative stress
cterial products can reach the brain via 1. systemic circulation and/or neural
his would increase 3. AD-specific pathology, 4. neurodegeneration, and 5.
would further amplify these effects through glial priming.
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bacterial dysbiosis [32] and severe local inflammatory re-
sponses. It is now accepted that PerioD is more severe
(destructive) in DS than in non-DS subjects (review [30]).
This localized inflammation combined with heavy bacterial
burden could contribute to an elevated systemic inflamma-
tion.
Based on the previous information, hypothetically, peri-
odontal bacteria, bacterial products, and periodontal-derived
cytokines produced locally and systemically could reach the
brain and amplify brain cytokine pools [58]. The keystone
pathogens P. gingivalis, T. forsythia, and T. denticola have
survival advantage and ability to reach distant sites such as
the brain. Then, bacteria, their products, and cytokines will
act on the already primed glial cells because of the DS genetic
factors, resulting in an amplified neuroinflammation and pro-
gression of AD. Another potential mechanism may involve
modulation of the clearance pathways affecting the amyloid
breakdown such as secretory and endosomal system [20,22].
DS subjects have also a pro-inflammatory phenotype that
has been implicated in AD of DS [26]. This mechanism
certainly can account independently for the pathogenesis of
AD of DS. However, it can also enhance the effect of PerioD
on the brain. The pro-inflammatory phenotype has been found
to prime the glia, and as described earlier, primed glia re-
sponds to stimulation more dramatically than the non-
primed ones [28]. Furthermore, some studies including ours
showed that when peripheral infectious/inflammatory condi-
tions are associated with a pro-inflammatory phenotype, the
effect of these conditions on the brain is significantly more
than predicted by either of them, thus suggesting a modifying
effect [10–12,59]. Therefore, the periodontal infectious/
inflammatory burden in DS subjects could cause more and
earlier brain damage than in non-DS subjects.
A sustained brain inflammation would upregulate the
expression of already triplicated APP gene and contribute
sooner to brain amyloid accumulation. Supportive of this
model, APP expression in the brain of DS is significantly
higher than predicted by the gene triplication suggesting that
other factors could turn on this gene expression. Cytokines
and LPS are candidates as they were found to consistently
stimulate amyloid synthesis and induce cognitive impairment
[7]. Our own studies showed that in NL subjects, measures of
history of PerioD associatedwith amyloid accumulation in the
brain [58] and affect tau protein hyperphosphorylation [36].
In summary, we propose that PerioD could affect the AD
progression in DS subjects. PerioD occurs early in life and,
therefore, preventative strategies could be instituted before
the induction of AD-specific pathology. Assessing these pre-
ventive effects in AD pathogenesis requires longitudinal
cohort studies. In non-DS AD, these cohort studies are diffi-
cult and expensive to implement. By comparison, examining
the role of PerioD in DSmay provide us with relative fast an-
swers [60]. Moreover, because PerioD may appear before
the AD-specific pathology, a causal effect may be possible
to be determined.Acknowledgments
We acknowledge that many relevant publications could not be
cited and apologize to all the authors we did not cite because of
the Journal’s constrain. This study was supported by National
institutes of Health (NIH)/National Institute on Aging grants
AG035137, AG032554, AG12101, AG022374, and
AG13616, NIH DE023139-02, Alzheimer’s Association
NIRG-12-173937, and NIH/NCATSUL1 TR000038. Conflict
of interest: No conflict of interest is reported for A.R.K., M.J.,
P.C., R.G.C.,D.S., K.R.C.A.,M.R., A.M., J.O.F., S.V.,M.C.-I.,
and B.B. M.J. de Leon has a patent on an image analysis tech-
nology that was licensed toAbiant Imaging, Inc., byNYU, and
has a financial interest in this license agreement, and NYU
holds stock options on the company. M. de Leon has received
compensation for consulting services from Abiant Imaging.
Dr L. Glodzic was a principal investigator on an Investigator-
Initiated project funded by Forest Laboratories and received an
honorarium for serving as a consultant to Roche Pharma. Con-
tributors: A.R.K., M.J.de.L., and J.F. wrote the manuscript. All
the other authors reviewed the manuscript and contributed
with the scientific literature, concepts, and modeling. All au-
thors reviewed the manuscript for intellectual content and
approved the final draft.RESEARCH IN CONTEXT
1. Systematic review: We searched PubMed up to
October 2015, for English articles with search terms
“periodontal disease,” “inflammation,” “infections,”
“brain,” “amyloid,” “pathogenesis,” “cognition,”
“Alzheimer’s disease,” “Down syndrome,” and “tri-
somy 21” and reviewed the articles referenced by
the articles identified in search.
2. Interpretation: Although most people with Down
syndrome (DS) acquire Alzheimer’s disease (AD)
as they age, AD onset is highly variable because of
genetic and possible environmental factors. Data
exist linking inflammation to AD of DS type. There-
fore, peripheral inflammation/infections such as peri-
odontal disease could contribute to AD progression
in DS subjects. In contrast with the general popula-
tion, DS has aggressive periodontitis with early onset
and significant bacterial/inflammatory burden.
Therefore, it could contribute to AD pathogenesis
and even its onset. This review offers a hypothetical
mechanistic link between periodontitis and AD in DS
population.
3. Future directions: This mechanistic hypothesis must
be investigated. If true, it would have tremendous im-
plications.
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